Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading ...

PumasAI, a science-first organization that turns data into life-saving decisions faster, today announced a major presence at ...

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data ...

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator ...

Ogbonnaya Onu Polytechnic Aba announces new Education Technology courses to boost digital skills and partners with NDLEA to ...

When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.

At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people ...

In this free webinar, see how respiratory drug development teams can strengthen spirometry oversight and improve respiratory endpoint data quality.

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Receipt of previous ...

Replacing a hydrogen atom in the drug with a boron-fluorine compound, boracycle, opens up great opportunities to modify the drug's properties. In this illustration, the boron-fluorine compound has ...

2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for ...

Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process. Traditional techniques, like high-throughput screening, offer an ...